Recent Headlines
Creative Diagnostics Introduces Plaque Reduction Assay Service for Research Applications
Creative Diagnostics recently introduced Plaque Reduction Assay services to detect antibodies from testing serum and viruses within diseased materials to diagnose viral infectious diseases. - December 28, 2022 - Creative Diagnostics
Paras Biopharmaceuticals Creates Excellence with “Continuous Biomanufacturing”: Achieves Objectives of “High Productivity & Biomanufacturing Innovation”
With 6 years of dedicated work at Paras Biopharmaceuticals and the use of Paras Biopharmaceuticals’ unique technology platform (which comprises of Bioproduction technologies for economical production of biologics), the company is pleased to announce that an excellent scale-up production process is achieved with “Continuous Biomanufacturing.” - December 19, 2022 - Paras Biopharmaceuticals Finland Oy
Paras Biopharma Streamlines Offerings as “Biologics CDMO” and Biosimilar Co-Development as “Paras Biologics”
Paras Biopharmaceuticals Finland Oy today revealed that the company has streamlined and enhanced its business activities with the establishment of a division called, Paras Biologics. In addition to its existing biologics CDMO activities and capabilities (this division is now referred to as Paras Biopharma), the creation of Paras Biologics enhances the company’s biologics and biosimilar pipeline for co-development and licensing opportunities. - December 11, 2022 - Paras Biopharmaceuticals Finland Oy
Clinical Research Organization, Huntington Study Group “Firsts” Continue
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) through its Clinical Research Organization (CRO), HSG Clinical Research, Inc. (HSGCR) continues making groundbreaking progress in the HD world. At their Annual Meeting in November, the... - December 05, 2022 - Huntington Study Group
Paras Biopharmaceuticals Finland Oy is Highly Recommended for Biologics CDMO – Development / Scale-up & Production of Biologics by Innovative USA Biopharma Company
Paras Biopharmaceuticals is pleased to announce that the company has been highly recommended for its Biologics CDMO – development / scale-up and production capabilities. The Paras Biopharmaceuticals Team has successfully completed multiple biologics projects in 2022. - November 29, 2022 - Paras Biopharmaceuticals Finland Oy
Huntington Study Group Annual Meeting
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD), recently held its 29th Annual Meeting in Tampa, FL. This renowned meeting brings together HD thought leaders, scientific experts, industry partners and sponsors, advocacy groups, and... - November 29, 2022 - Huntington Study Group
Creative Diagnostics Introduces Hemagglutination Assay Service for Scientific Applications
Creative Diagnostics recently introduced Hemagglutination Assay services for influenza vaccine, diagnostic, and surveillance communities to measure virus and antibody titers and monitor influenza subtypes. - November 26, 2022 - Creative Diagnostics
Creative Diagnostics Announces New Polyethylene Glycol Antibodies Detection Kits
Creative Diagnostics announced the launch of a panel of anti-PEG IgG or IgM ELISA kits with different species reactivity to detect anti-PEG IgG or IgM in serum and plasma. - November 26, 2022 - Creative Diagnostics
Marty Rosenberg joins the Board of Scientific Advisors at Microvascular Therapeutics.
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Marty Rosenberg to the MVT Board of Scientific Advisors. Mr. Rosenberg brings a broad experience with the clinical development and global regulatory approval process for... - November 25, 2022 - Microvascular Therapeutics, Inc.
David Lim Joins the Team at Microvascular Therapeutics as Director of Finance
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of David Lim as Director of Finance at MVT. Mr. Lim brings a broad experience with the business development and strategic financing for diagnostic pharmaceuticals across all... - November 25, 2022 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Receives Funds from the National Cancer Institute (NCI) for Its Brain Tumor Program
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Cancer Institute (NCI). Emmanuelle Meuillet, Chief Scientific and Operating Officer at MVT said, “We are... - November 18, 2022 - Microvascular Therapeutics, Inc.
Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce the results from the novel HD-Net survey, which examined the United States Huntington’s disease (HD) care delivery in a variety of clinic settings by HD specialists and non-specialists. - October 25, 2022 - Huntington Study Group
Creative Diagnostics Introduces Fluorometric Neuraminidase Assay Service for High-Throughput Discovery
As an expert in the antiviral field providing solutions to assist virology and microbiology research, Creative Diagnostics recently introduced Fluorometric Neuraminidase Assay services to the global research community, suitable for functional detection of NI-resistant viruses in mixed virus... - October 23, 2022 - Creative Diagnostics
Creative Diagnostics Launches Monkeypox Virus Antigens and Antibodies to Accelerate MPXV Study
Creative Diagnostics announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. - October 23, 2022 - Creative Diagnostics
Huntington Study Group Announces myHDstory™ Pilot Study: Making HD Voices Heard Has Reached Target Enrollment
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce that the pilot study, Making HD Voices Heard, on the new online research platform, myHDstory™, has reached its enrollment target. “The HSG... - October 18, 2022 - Huntington Study Group
Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the Unified Huntington’s Disease Rating Scale
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) for over 30 years, together with its Clinical Research Organization (“CRO”), the HSG Clinical Research, Inc., today announces the enrollment of the first participant of its... - October 12, 2022 - Huntington Study Group
Mirror Biologics, Inc. Announces Additional $20 Million Investment to Close Out $30 Million Series A Investment Round
Mirror Biologics, Inc., a clinical stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round with Bradbury Asset Management (Hong Kong), Limited. Bradbury provided an initial $10 million tranche for this round in... - October 11, 2022 - Mirror Biologics, Inc.
Creative Diagnostics Announces the Launch of SARS-CoV-2 ADE Assay
Creative Diagnostics announced the launch of SARS-CoV-2 ADE Assay to support laboratory scientists for SARS-CoV-2 vaccine research. - September 28, 2022 - Creative Diagnostics
Creative Diagnostics Introduces Highly Sensitive Cytopathic Effect Inhibition Assay Service
Creative Diagnostics introduced the Cytopathic Effect Inhibition Assay Service of high assay sensitivity and accuracy. - September 28, 2022 - Creative Diagnostics
NuvOx Appoints Dr. Katy Peters to SAB
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Katy Peters to its Scientific Advisory Board (SAB). Dr. Katy Peters, MD, Ph.D. FAAN is an associate professor of neurology and... - September 22, 2022 - NuvOx Therapeutics
New Decentralized Clinical Trial (DCT) Patient Satisfaction and Participation Report
800 Current and Future Clinical Trial Participants Link Satisfaction and Willingness to Participate with Decentralized Strategies - September 21, 2022 - Life Science Strategy Group, LLC
Paras Biopharmaceuticals Finland Oy Has Been Identified as One of the "Fastest Growing Companies in the Nordic Biotechnology Therapeutics & Diagnostics Industry"
Paras Biopharmaceuticals is pleased to announce that the company has been identified as one of the Fastest Growing Companies in the Nordic Biotechnology Therapeutics and Diagnostics industry by Plimsoll Publishing UK. - September 01, 2022 - Paras Biopharmaceuticals Finland Oy
Creative Diagnostics Launches Custom Virus Production Service
Creative Diagnostics has recently introduced the research community with customized virus production services. - August 26, 2022 - Creative Diagnostics
Creative Diagnostics Launches New Livestock Infectious Diseases Antigens
Creative Diagnostics announced the launch of more than 20 antigens for the development of veterinary infectious diseases diagnostics and vaccines. - August 26, 2022 - Creative Diagnostics
CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods
The Cayman Biomedical Research Institute (CABRI) is offering research grants in amounts up to $100,000 to support essential research on specialized pro-resolving mediator (SPM) analytical methods. - August 26, 2022 - Cayman Chemical Company
Deadline Extended: CABRI Announces Undergraduate Fellowships and Scholarship Program
The Cayman Biomedical Research Institute (CABRI) is accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted from August 22 until September 18, 2022. - August 26, 2022 - Cayman Chemical Company
Pharma CI Conference Returns Next Month: Meet Hundreds of Industry Leaders at the Top Event for 15+ Years
Ready, set, engage! The Pharma CI USA Conference & Exhibition is back in person and ready to deliver the industry-leading experience that has made Pharma CI the gold standard event for more than fifteen years. The much-anticipated return happens this September 21-22 at the Newark Liberty... - August 18, 2022 - Pharma CI Conference
Peptineo, LLC Selected by EPA to Provide EPA Nationwide Coverage for Point of Care (POC) COVID-19 Testing
The Environmental Protection Agency (EPA), Cincinnati Acquisition Division (CAD), has awarded Peptineo LLC, an emerging aerospace, health services, and defense solutions company, a three-year Blanket Purchase Agreement (BPA) to support a comprehensive COVID-19 testing program in support of the... - August 07, 2022 - Peptineo
Creative Diagnostics Launches Monkeypox Virus Antibodies and Antigens to Support MPXV Research
Creative Diagnostics announced the launch of several Monkeypox Virus Antibodies and Antigens for the detection of Monkeypox viruses. - July 22, 2022 - Creative Diagnostics
Creative Diagnostics Introduces New Cell-Based ELISA Services
Creative Diagnostics is offering comprehensive services for Cell-based ELISA that can measure the reduction of viral antigens in infected cells using anti-virus antibodies or compounds. - July 22, 2022 - Creative Diagnostics
Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies
Creative Diagnostics announced the release of new measles virus antigens suitable for both IgM and IgG detection. - June 11, 2022 - Creative Diagnostics
Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety
Creative Diagnostics introduced CC50/IC50 testing services with a high level of detection sensitivity and accuracy. - June 11, 2022 - Creative Diagnostics
Creative Diagnostics Launches Antibody-Dependent Enhancement Assay Services
Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. - May 26, 2022 - Creative Diagnostics
Creative Diagnostics Announces Antigens for Epstein-Barr Virus Antibody Tests
Creative Diagnostics recently launched recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). - May 26, 2022 - Creative Diagnostics
Molekule Consulting Announces the Launch of E.U. - Based Operations
Molekule Consulting announces the launch of an E.U. - based business / Molekule Hub continuing their focus on the development of global strategy and advisory services for the biopharmaceutical sector. - May 24, 2022 - Molekule Consulting
NuvOx Pharma Announces Issuance of a New Patent
NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof.” - May 19, 2022 - NuvOx Therapeutics
NuvOx Appoints Dr. Robert King to SAB
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Robert King to its Scientific Advisory Board (SAB). Dr. King is a seasoned life science executive with over 30 years’... - May 11, 2022 - NuvOx Therapeutics
Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies
Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. - April 30, 2022 - Creative Diagnostics
Microvascular Therapeutics Finalizes Facility Certification for the Production of Its Product, MVT-100
Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. - April 21, 2022 - Microvascular Therapeutics, Inc.
NuvOx Technology Featured in Prominent Peer Review Journal
NuvOx Pharma’s technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, was featured in the prominent journal of Frontiers of Neurology. - April 19, 2022 - NuvOx Therapeutics
NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, finalized its manufacturing facility certifications for Phase IIb trials. - April 17, 2022 - NuvOx Therapeutics
Dr. Claudia C. Cotca of C3 Think Tank Appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health
Dr. Claudia C. Cotca of C3 Think Tank appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health. Together with leadership and military health experts, stakeholders and program officers, Dr. Claudia C Cotca will help support and contribute to the scope and mission of ATARC’s Warfighter Health in incorporating responsibly artificial intelligence in military medicine. - April 13, 2022 - C3 Think Tank
Microvascular Therapeutics Receives Funds from Commercialization Readiness Program for the Development of Its Ultrasound Contrast Agent, MVT-100
MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are... - April 09, 2022 - Microvascular Therapeutics, Inc.
Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens
Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens. - March 31, 2022 - Creative Diagnostics
NuvOx Receives Notice from the Breakthrough DOD Award for Its Immuno-Oncology Program
On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a... - March 05, 2022 - NuvOx Therapeutics
Timothy Healey Joins the Board of Director at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022 - Microvascular Therapeutics, Inc.
NuvOx to Participate in the BIO CEO Investor Conference
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be... - February 11, 2022 - NuvOx Therapeutics
ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit
ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022 - Microvascular Therapeutics, Inc.
Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022 - Microvascular Therapeutics, Inc.
NuvOx to Present at Various Bio Forums in JPM Week
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in... - January 14, 2022 - NuvOx Therapeutics